STOCK TITAN
  1. Home
  2. News
  3. DGX

Quest Diagnostics Inc. - DGX STOCK NEWS

Welcome to our dedicated page for Quest Diagnostics news (Ticker: DGX), a resource for investors and traders seeking the latest updates and insights on Quest Diagnostics stock.

Quest Diagnostics Inc. (NYSE: DGX) is a leading provider of diagnostic testing, information, and services in the United States, enabling people to make informed health decisions. The company provides diagnostic insights derived from the world’s largest database of clinical lab results, which aids in identifying and treating diseases, promoting healthy behaviors, and improving healthcare management.

Quest Diagnostics serves one in three adult Americans and half of the physicians and hospitals in the United States. Its workforce of nearly 50,000 employees is dedicated to transforming lives by providing actionable diagnostic insights. The company offers the broadest test menu available, with over 3,000 different tests, and has a strong focus on cancer diagnostics, anatomic pathology, and interpretive consultations through its medical and scientific staff of approximately 900 M.D.s and Ph.D.s.

In recent years, Quest Diagnostics has been at the forefront of innovation in diagnostic testing. The company has significantly invested in AI and digital pathology to enhance the accuracy and efficiency of cancer diagnoses. A notable collaboration with PathAI aims to accelerate the adoption of digital and AI pathology technologies, thereby improving the quality, speed, and efficiency of diagnosing cancer and other diseases. This partnership includes the acquisition of PathAI Diagnostics’ state-of-the-art digitized laboratory in Memphis, Tennessee, which will serve as Quest’s AI and digital R&D and solutions center.

Financially, Quest Diagnostics has shown robust performance, with annual revenues reaching $7.4 billion in 2014. The company continues to strengthen its market presence through strategic acquisitions and partnerships, expanding its services and enhancing its capabilities in specialized pathology services. The integration of digital and AI technologies across its operations has improved quality, efficiency, and customer satisfaction, positioning Quest Diagnostics as a leader in the diagnostic services industry.

Quest Diagnostics' extensive clinical testing network includes roughly 2,300 patient service centers, numerous doctors' offices, and hospitals nationwide. The company also provides clinical trials testing, risk assessment services, and information technology solutions through its diagnostic solutions segment.

By leveraging its comprehensive diagnostic insights, Quest Diagnostics aims to empower individuals and healthcare providers to make informed decisions that lead to better health outcomes, ultimately contributing to a healthier world.

News

Quest Diagnostics to Speak at the Barclays 26th Annual Global Healthcare Conference

Rhea-AI Summary
Quest Diagnostics Incorporated (DGX) announced that Sam Samad, CFO, will speak at the Barclays Global Healthcare Conference to discuss the company's strategy and performance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.39%
Tags
conferences
-
News

Quest Diagnostics and Instacart Collaborate to Reduce Food Insecurity Across the United States with Integrated Patient Health Coaching and Nutritious Grocery Delivery

Rhea-AI Summary
Pack Health, a Quest Diagnostics company, collaborates with Instacart to provide grocery delivery services to individuals in coaching programs, addressing social determinants of health. The partnership aims to improve food access and healthy eating habits for underserved communities, offering nutrition education, coaching, and fresh food delivery. This initiative combines Instacart's reach and technology with Pack Health's expertise in patient engagement, providing a comprehensive nutrition solution for health plan members.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.37%
Tags
none
-
News

Freenome Raises $254 Million in New Funding to Accelerate its Platform for Early Cancer Detection

Rhea-AI Summary
Freenome secures $254 million in funding led by Roche to advance cancer detection tests. The funds will support the development of early cancer detection tests and expand the multiomics platform capabilities. Investors include Roche, a16z Life Sciences Growth Fund, and Quest Diagnostics (DGX). Freenome aims to revolutionize personalized healthcare with groundbreaking blood-based screening technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.56%
Tags
none
News

Quest Diagnostics Debuts MelaNodal Predict™ Test, Personalizing Melanoma Risk Prediction to Help Patients Forgo Invasive Surgery

Rhea-AI Summary
Quest Diagnostics (DGX) launches MelaNodal Predict™, a gene expression test to aid melanoma treatment decisions. The test shows over 90% survival rate for low-risk patients. The partnership with SkylineDx aims to provide personalized care and reduce unnecessary surgeries.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.65%
Tags
none
-
News

First PFAS "Forever Chemicals" Consumer-Initiated Blood Test with Physician Consult Launches on questhealth.com

Rhea-AI Summary
Quest Diagnostics (DGX) introduces a consumer-initiated, physician-ordered blood-draw test for PFAS chemicals, addressing elevated exposure risks. The test detects and measures PFAS identified by National Academies of Sciences, Engineering, and Medicine, catering to various organizations for workforce, community, and research population testing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.58%
Tags
none
-
News

Quest Diagnostics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Guidance for Full Year 2024; Increases Quarterly Dividend 5.6% to $0.75 Per Share

Rhea-AI Summary
Quest Diagnostics (DGX) reported a 1.9% decrease in fourth quarter revenues, with a 95.4% increase in reported diluted EPS and an 8.6% increase in adjusted diluted EPS. Full year revenues were down 6.4% from 2022, with reported diluted EPS down 6.0% and adjusted diluted EPS down 12.5%. The company expects full year 2024 reported diluted EPS to be between $7.69 and $7.99, and adjusted diluted EPS to be between $8.60 and $8.90. Quest Diagnostics' Board of Directors has authorized a 5.6% increase in its quarterly dividend. The company estimates full year 2024 guidance with a net revenues increase of 1.1% to 2.1%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.98%
Tags
dividends earnings
News

Ten Years Running: FORTUNE Names Quest Diagnostics one of 2024 "World's Most Admired Companies"

Rhea-AI Summary
Quest Diagnostics (NYSE: DGX) has been recognized as one of FORTUNE's World's Most Admired Companies in 2024 for the tenth consecutive year. The company scored high marks in people management, use of corporate assets, and social responsibility, making it one of only five companies to attain Most Admired status in the 'Health Care: Pharmacy and Other Services' industry. The recognition is based on nine criteria of corporate reputation, including innovation, quality of management and products, and social responsibility. Quest Diagnostics' Chairman, CEO, and President, Jim Davis, expressed gratitude to the company's dedicated colleagues for their role in achieving this honor.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.31%
Tags
none
-
News

Fitbit and Quest Diagnostics Collaborate To Advance Research on the Use of Wearable Devices To Improve Metabolic Health

Rhea-AI Summary
Fitbit and Quest Diagnostics (NYSE:DGX) have announced a collaboration to study the potential of wearable devices to improve metabolic health, aiming to evaluate the effect of wearables on users' behaviors based on objective laboratory test results. The Wearables for Metabolic Health (WEAR-ME) pilot study will pair behavioral and biometric data from Fitbit devices with health insights from Quest Diagnostics' laboratory tests to explore ways data can be combined and analyzed to improve the assessment and management of metabolic health and help to inform the prevention of disease. The study will invite approximately 1,500 existing Fitbit users to join and consent to share three months of their Fitbit data and receive laboratory testing at no cost using a panel of blood tests specifically designed to assess metabolic health. This study is expected to be completed in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.84%
Tags
none
-
News

Haystack Oncology, developer of Haystack MRD™, and TriSalus Life Sciences collaborate in connection with the clinical development of TriSalus' TLR9 agonist in hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and pancreatic adenocarcinoma

Rhea-AI Summary
Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company, has entered a research collaboration with TriSalus Life Sciences to evaluate therapeutic response and provide molecular insights in connection with the clinical development of TriSalus' SD-101, an investigational class C toll-like receptor-9 (TLR9) agonist. The collaboration aims to overcome challenges associated with treating liver and pancreatic tumors by utilizing Haystack MRD™ technology to accurately detect circulating tumor DNA (ctDNA) with unparalleled sensitivity in patients with low tumor burden and in clinically challenging cancer types. The partnership is focused on supporting the clinical development of SD-101 in combination with TriSalus' unique therapy delivery technology, Pressure-Enabled Drug Delivery™ (PEDD™). This collaboration has the potential to offer better therapeutic options for patients with liver and pancreatic tumors, addressing significant challenges in the development of immunotherapies for these cancer types.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.4%
Tags
clinical trial
News

Quest Diagnostics to Release Fourth Quarter and Full Year 2023 Financial Results on February 1, 2024

Rhea-AI Summary
Quest Diagnostics (DGX) will report Q4 and full year 2023 financial results on February 1, 2024. The company will hold a conference call to discuss the results and provide access to a live webcast. Participants can access the call and webcast via dial-in or online replay. The company encourages participants to read its periodic reports on file with the SEC, including risk factors and historical results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.1%
Tags
earnings

FAQ

What is the current stock price of Quest Diagnostics (DGX)?

The current stock price of Quest Diagnostics (DGX) is $153.1 as of December 20, 2024.

What is the market cap of Quest Diagnostics (DGX)?

The market cap of Quest Diagnostics (DGX) is approximately 17.0B.

What does Quest Diagnostics do?

Quest Diagnostics provides diagnostic testing, information, and services that help healthcare providers and patients make informed health decisions. The company offers a broad range of tests and diagnostic insights derived from the world’s largest database of clinical lab results.

How many people does Quest Diagnostics serve annually?

Quest Diagnostics serves one in three adult Americans and half of the physicians and hospitals in the United States each year.

What are some recent achievements of Quest Diagnostics?

Recently, Quest Diagnostics has partnered with PathAI to enhance its AI and digital pathology capabilities. The acquisition of PathAI Diagnostics' digital laboratory will serve as a new AI and digital R&D center, improving cancer diagnosis quality and efficiency.

What kind of tests does Quest Diagnostics offer?

Quest Diagnostics offers over 3,000 different tests, including clinical testing, anatomic pathology, esoteric testing, and substance abuse testing.

What is the company's approach to innovation?

Quest Diagnostics focuses on incorporating AI and digital technologies into its diagnostic services to enhance accuracy, efficiency, and accessibility of its offerings. The company also pilots new technologies and expands its capabilities through strategic partnerships and acquisitions.

How extensive is Quest Diagnostics' clinical testing network?

Quest Diagnostics operates an extensive clinical testing network with approximately 2,300 patient service centers, as well as numerous doctor’s offices and hospitals across the United States.

What role do partnerships play at Quest Diagnostics?

Partnerships, such as the recent collaboration with PathAI, play a crucial role in Quest Diagnostics' strategy to integrate advanced technologies and expand its capabilities in specialized diagnostic services.

How does Quest Diagnostics contribute to healthcare management?

Quest Diagnostics provides diagnostic insights that help identify and treat diseases, inspire healthy behaviors, and improve healthcare management. These insights support more informed decision-making by both patients and healthcare providers.

What are the company’s future plans?

Quest Diagnostics plans to continue expanding its capabilities in AI and digital pathology, enhance its clinical testing services, and maintain its leadership in diagnostic information services. The company aims to leverage its diagnostic insights to empower better healthcare outcomes globally.

How does Quest Diagnostics ensure the quality of its services?

Quest Diagnostics employs nearly 50,000 dedicated professionals, including about 900 M.D.s and Ph.D.s, and integrates cutting-edge technology and rigorous quality control measures across its operations to ensure high-quality diagnostic services.

Stock DGX logo
Quest Diagnostics Inc.

NYSE:DGX

DGX Rankings

#604 Ranked by Market Cap
#1414 Ranked by Dividends

DGX Stock Data

16.99B
111.10M
0.43%
91.55%
2.32%
Diagnostics & Research
Services-medical Laboratories
Link
United States of America
SECAUCUS